Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 11:9:2061.
doi: 10.3389/fimmu.2018.02061. eCollection 2018.

The Dual Nature of Type I and Type II Interferons

Affiliations
Review

The Dual Nature of Type I and Type II Interferons

Amanda J Lee et al. Front Immunol. .

Abstract

Type I and type II interferons (IFN) are central to both combating virus infection and modulating the antiviral immune response. Indeed, an absence of either the receptor for type I IFNs or IFN-y have resulted in increased susceptibility to virus infection, including increased virus replication and reduced survival. However, an emerging area of research has shown that there is a dual nature to these cytokines. Recent evidence has demonstrated that both type I and type II IFNs have immunoregulatory functions during infection and type II immune responses. In this review, we address the dual nature of type I and type II interferons and present evidence that both antiviral and immunomodulatory functions are critical during virus infection to not only limit virus replication and initiate an appropriate antiviral immune response, but to also negatively regulate this response to minimize tissue damage. Both the activating and negatively regulatory properties of type I and II IFNs work in concert with each other to create a balanced immune response that combats the infection while minimizing collateral damage.

Keywords: immunoregulation; innate immunity; interferon-γ; type I interferon; virus infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The role of IFNs in the innate immune response to HSV-2 infection. (1) IFN-β is produced at 12 h post-infection and through autocrine and paracrine signaling places surrounding cells into an antiviral state. (2) The IFN-β produced at 12 h post-infection also increases production of CCL2 between days 1 and 2 post-infection, which results in inflammatory monocyte recruitment and has been implicated in NK cell recruitment. (3) The recruited inflammatory monocytes result in release of IL-18, which stimulates NK cells to produce IFN-γ at 48 h post-infection. (4) A second wave of type I IFNs, including both IFN-α and IFN-β, are detected at 48 h post-infection. (5) Both IFN-γ and the type I IFNs produced at 48 h post-infection enhance APC antigen presentation capacities to stimulate a Th1 adaptive immune response. (6) Simultaneously, the type I IFNs at 48 h inhibit ILC2-mediated virus-induced immunopathology. IFN-γ, supporting the negative regulatory effects of type I IFN, also suppresses ILC2-mediated immunopathology.

Similar articles

Cited by

References

    1. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, et al. . Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell (1990) 62:379–90. 10.1016/0092-8674(90)90374-N - DOI - PubMed
    1. Lee AJ, Chen B, Chew MV, Barra NG, Shenouda MM, Nham T, et al. . Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. J Exp Med. (2017) 214:1153–67. 10.1084/jem.20160880 - DOI - PMC - PubMed
    1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. (2008) 9:503–10. 10.1038/ni1582 - DOI - PubMed
    1. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. (2005) 5:375–86. 10.1038/nri1604 - DOI - PubMed
    1. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2013) 339:786–91. 10.1126/science.1232458 - DOI - PMC - PubMed

Publication types

Grants and funding